Tissue factor (TF) is a low molecular weight glycoprotein that initiates the clotting cascade and is considered to be a major regulator of coagulation, hemostasis, and thrombosis. TF is not expressed in the intima or media of normal adult blood vessels. Accordingly, it has been hypothesized that the initiation of intravascular coagulation may require the "induced" expression of TF in the vessel wall. We report that TF mRNA and protein are rapidly and markedly induced in early and late passaged vascular smooth muscle cells (VSMC) by growth factors (serum, platelet-derived growth factor, epidermal growth factor), vasoactive agonists (angiotensin II), and a clotting factor (a-thrombin). The induction of TF mRNA by these agents is dependent upon mobilization of intracellular Ca2" and is blocked by Ca2" chelation. In contrast to other growth factorresponsive genes, such as KC and c-fos, downregulation of protein kinase C activity by prolonged treatment with phorbol esters fails to block agonist-mediated TF induction. This raises the possibility that protein kinase C activation may not be necessary for TF mRNA induction in VSMC. VSMC may play a role in the generation or propagation of thrombus through the induction of TF, particularly in settings, such as those associated with acute vessel injury, where the endothelium is denuded and the VSMC are exposed to circulating blood. (J. Clin. Invest.
Introduction
Tissue factor (TF)' is a low molecular weight glycoprotein that initiates the clotting cascade and is considered to be a major regulator of coagulation, hemostasis, and thrombosis ( 1, 2) . Unlike other coagulation factors, TF is not normally found in concentration; CS, calf serum; EGF, epidermal growth factor; PDBu, phorbol 12,13-dibutyrate; PDGF, platelet-derived growth factor; TF, tissue factor; VSMC, vascular smooth muscle cells. the circulation, but is located on the plasma membranes ofcells not usually in contact with the blood. Human TF consists of three domains: a short cytoplasmic domain of 21 residues, a single transmembrane domain of23 residues, and a large extracellular domain of 219 residues. TF binds to Factor VII/VIa, and the resulting complex acts as a catalyst for the conversion of Factors IX and X to IXa and Xa, respectively, thus triggering the clotting cascade.
TF is not expressed in the intima or media of normal adult blood vessels (3, 4) . This has led some to hypothesize that the initiation of intravascular coagulation requires the "induced" expression of TF (3) . Wilcox et al. (4) examined normal internal mammary arteries using both immunohistochemistry with an anti-human TF antibody and in situ hybridization with a human TF RNA probe. Endothelial cells did not contain detectable TF mRNA and protein in any sample examined. The media from all arteries tested (including coronary and aorta) contained only rare cells with TF mRNA and none with TF protein. In contrast, the adventitial fibroblasts showed intense TF immunostaining and mRNA hybridization in all arterial samples. When atherosclerotic plaques from carotid endarterectomy specimens were examined by similar methods, TF mRNA and protein remained absent from the endothelium, but were identified in mesenchymal-like intimal cells (presumably vascular smooth muscle cells [ VSMC ] ) as well as in foam cells and monocytes adjacent to cholesterol clefts, and in the extracellular matrix. These authors suggested that the induction ofTF in the atherosclerotic plaque might contribute to the hyperthrombotic state of atherosclerotic vessels. In addition to the above work, functional TF has also been demonstrated in ballooned (deendothelialized) human and rabbit arteries, suggesting that its induction may also contribute to the thrombotic response accompanying acute vessel injury (5) .
Experiments in cell culture have demonstrated TF to be highly inducible by a variety of agents. In endothelial cell culture, TF mRNA and/or procoagulant activity is induced by phorbol esters (6) (7) (8) , tumor necrosis factor (6, 9, 10), endotoxin (7, 1 1 ), interleukin 1 ( 12, 13), and a-thrombin ( 14) .
Similar results have been found in monocytes, where TF mRNA and/or procoagulant activity is stimulated by a variety of mediators of inflammation and antigen-specific cellular immune responses (for review, see reference 2). In mouse fibroblasts, TF has been found to be a member ofthe class of"immediate early" genes induced by serum and growth factors, including platelet-derived growth factor (PDGF), fibroblast growth factor, and transforming growth factor (3 (15, 16 (22) . Agarose gel electrophoresis, transfer to nitrocellulose and hybridization to 32P-labeled DNA were as previously described (23) . Prehybridization and hybridization were performed at 42°C. Final washes for all blots were in 0.1 X standard saline citrate (SSC) (1 x = 0.15 M NaCl/ 0.0 15 M sodium citrate, pH 7) and 0.1% SDS at 65°C for 1 h. The full-length insert from mouse TF ( 15) was labeled by random oligomer priming to a specific activity of > 10' cpm/,ug and used at 2 X 106 cpm/ ml. As a control, filters were also hybridized with cDNA encoding the constitutively expressed smooth muscle myosin regulatory light chain (24) . All experiments shown in the figures represent RNA blots in which all lanes had equal loading as confirmed both by staining of 18s and 28s ribosomal RNA with ethidium bromide and by hybridization with the regulatory light chain.
Analysis oftissuefactor activity. Quiescent and stimulated VSMC cultures were washed twice with 20 mM Hepes, pH 7.6, 140 mM NaCl, and 4 mM EDTA, scraped into 1 ml of20 mM Hepes, pH 7.6, 140 mM NaCl (40C), and sonicated at 20 kHz for 20 s (model W375; Heat Systems-Ultrasonics Inc., Farmingdale, NY). 50-MIl aliquots were assayed in duplicate for TF activity using modifications of the standard two-stage procedure (25, 26) . Each aliquot was incubated at 370C for 1 min with 50 Ml ofrat Factor VII-X concentrate (see below) and 50 M1 of a 5 mM CaCl2, 12.5 MM phosphatidyl serine/phosphatidyl choline (30/70; wt/wt) solution. 50 Ml of human plasma (derived from an individual donor, aliquoted into single-use samples, and stored at -800C) was then added at 370C and the clotting time was recorded. To generate a standard TF activity curve, a mouse brain homogenate was prepared as follows: 1.5 g of stripped mouse brain (Pel-Freez Biologicals, Rogers, AR) was suspended in 15 ml isotonic saline, disrupted by sonication, centrifuged at 1,000 g x 15 min, and the supernatant aliquoted and stored at -80°C. The protein concentration ofthe homogenate was determined using Bradford reagent (protein assay; Bio-Rad Laboratories, Richmond, CA) with BSA as a standard. When assayed as above, Mg ofhomogenate generated a linear curve when plotted on a semi-log scale. The amount of protein required to produce a clotting time of 25 s was arbitrarily assigned a value of 100 activity units. TF activity in VSMC samples was expressed as activity units per mg of protein.
A crude concentrate of Factors X, VII, and VIla was prepared from mouse serum (Pel-Freez Biologicals) as previously described (26) with minor modifications. 7.6% sodium citrate ( 1 ml) and 1 M BaCl2 (2 ml) were added to 20 ml of serum, stirred for 30 min at 4°C, and precipitated by centrifugation at 3,000 g X 15 min. The precipitate was washed x 2 with 5 ml of 5 mM BaCl2, resuspended in 2 ml of 25% (NH4)2S04, 50 mM Tris-HCl (pH 7.5), and 0.1 M NaCl, and stirred for 30 min at 4°C. After centrifugation at 3,000 g X 15 min, the supernatant was collected, dialyzed overnight at 4°C against Tris-buffered saline. This stock concentrate was aliquoted and stored at -80°C. For TF assays, the stock was diluted 1 :10.
Results
Induction of TF mRNA in VSMC culture. To investigate the induction of TF mRNA in cultured VSMC, quiescent cells were treated with PDGF (50% pure; Collaborative Research Inc.) for the times indicated. Total RNA was harvested and RNA blot hybridization was performed using the full-length mouse TF cDNA ( 15) . mRNA corresponding to an 2-kb TF species was either not detectable (as depicted in Fig. 1 A) or barely detectable in quiescent VSMC. PDGF induced a rapid and marked rise in TF mRNA levels, beginning at 15 min and peaking between 75 and 90 min. The induction of TF mRNA was particularly short-lived in VSMC, with levels returning to baseline within 3-4 h. Quiescence was not a requisite for TF induction. VSMC cultures undergoing log-phase growth (75% confluence) had little (as shown in Fig. 1B) or no detectable TF mRNA 48 h after feeding with standard growth medium (DME + 10% CS). Upon addition of fresh DME + 10% CS, there was a rapid induction ofTF mRNA, with time course and levels similar to that found in quiescent VSMC following PDGF or serum stimulation. Neither the degree of confluence (50-1 00%) nor the passage number (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) c-fos and c-myc (28, 29) . PDGF, angiotensin II, and a-thrombin all stimulate protein kinase C ( 19, 20, 27) . Phorbol 12-myristate 13-acetate (PMA; 250 ng/ml), a potent activator of protein kinase C, induced TF mRNA with a time course and levels similar to those induced by other agonists (Fig. 5 A) The data described above demonstrate that TF gene expression is highly regulated in cultured VSMC. The time course of growth factor-induced TF mRNA expression is similar to that reported for 3T3 fibroblasts (15) , but considerably shorter than that found in most other studies employing endothelial cells, human fibroblasts or monocytes, where elevated levels persist for 8-24 h (reviewed in reference 2). TF mRNA thus has an unusually short half-life in VSMC. The induction ofTF mRNA in very early passages is of particular import. Aortic VSMC modulate from a contractile to a more fibroblast-like growth phenotype during multiple passaging in culture (30, 31 ) . This change in phenotype is associated with a loss ofactinmyosin filaments as well as a marked decrease in the expression of smooth muscle a-actin mRNA (32) . The finding that TF mRNA is induced in very early passages (passages 1-5) strongly argues that this induction is not an artifact of cell culture.
The induction of TF mRNA is associated with a marked increase in TF activity. The rise in TF activity is temporally associated with the increase in TF mRNA expression, suggesting that translation of TF into its active form occurs rapidly following elevation of TF mRNA levels. In contrast, TF activity persists at high levels for 4-8 h after the fall in TF mRNA expression, suggesting that the protein has a relatively long half-life. The early rise in TF activity contrasts with that previ- 550 Taubman et al.
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ously reported for smooth muscle cells derived from human saphenous veins, where there was a 24-h delay in TF activity after serum stimulation (17) . The early induction of TF mRNA and activity in VSMC derived from the arterial tree suggests that arterial VSMC may be more specialized than venous VSMC in their ability to mediate acute thrombosis. Alternatively, the difference in the time course ofTF induction may reflect a species-specific phenomenon (i.e., human vs. rat). An immediate response to a variety of agonists, including PDGF, angiotensin II, and a-thrombin, is the activation of phospholipase C. This enzyme hydrolyzes phosphatidylinositol-4,5-bisphosphate to generate the "second messengers," diacylglycerol and inositol trisphosphate. Diacylglycerol stimulates protein kinase C, whereas inositol trisphosphate mobilizes Ca2+ from intracellular stores. Activation of protein kinase C and mobilization of intracellular Ca2' have been shown to be involved in the induction of a number of early growth factorinducible genes ( 19, 20, (27) (28) (29) 33) . The Ca2+ ionophore, ionomycin, markedly induced TF mRNA in cultured VSMC. More significantly, the induction of TF in VSMC by a wide range of agonists, including PDGF, angiotensin II, and athrombin, was dependent upon mobilization of intracellular Ca2 . It has recently been shown, in bovine fibroblasts, pericytes, and kidney cells, that Ca2+ ionophore markedly increases TF activity on the cell membrane. This increase in activity is due to a process ofdeencryption, whereby increased intracellular Ca2+ causes a change in TF accessibility on the cell membrane, exposing previously encrypted (e.g., inactive) TF molecules (34). Thus, increases in intracellular Ca2+ may play a dual role in TF regulation, modulating both TF gene expression and TF protein activity.
The mechanism by which intracellular Ca2+ mobilization modulates the activation ofTF remains to be determined. Ca2+ may play a role in TF gene induction by directly activating a Ca2+-response element or by modulating the activity of a trans-acting factor(s), such as one that binds to a serum-or PDGF-response element. Ca2+ may also be a necessary co-factor in one or more steps ofthe signaling pathway leading to TF gene expression or regulation ofTF mRNA stability. For example, it has recently been reported that the inhibition of calmodulin by myosin light chain kinase peptide attenuated the expression of TF activity in human umbilical vein endothelial cells (35) . This report, along with several earlier reports employing very high doses of calmodulin antagonists (36, 37) , suggests that the effect of Ca2+ on TF induction may involve a calmodulin-sensitive pathway.
It has previously been shown that phorbol esters, which are activators of protein kinase C, induce high levels of TF mRNA in human endothelial cells and peripheral leukocytes (6) (7) (8) .
This report demonstrates that phorbol esters also induce TF mRNA in cultured VSMC, although the duration of TF mRNA expression is considerably shorter than that reported for endothelial cells or leukocytes. PDBu-mediated downregulation of cytosolic protein kinase C activity by 80-90% had no effect on the induction of TF mRNA by angiotensin II, athrombin, PDGF, or Ca2+ ionophore. This differs from other early growth factor-responsive genes, such as c-fos and KC, whose induction by these agonists is blocked by the identical downregulation protocol ( 19, 38) . Thus, the regulation of TF in VSMC appears to be distinct from other early growth factorinducible genes. These results raise the possibility that protein kinase C is not involved in agonist-mediated induction of TF mRNA. However, it is also possible that the downregulation protocol used in this study, while significantly reducing total protein kinase C activity, failed to block the activity of a specific protein kinase C isoform (39) responsible for the induction of TF mRNA. For example, Pettersen et al. (40) , have recently shown that while phorbol ester-mediated downregulation of protein kinase C activity did not block the induction of TF mRNA by interleukin-1 or lipopolysaccharide in human umbilical vein endothelial cells, high doses of specific inhibitors of protein kinase C, such as H7 or staurosporine, did. While preliminary observations (Taubman, M., J. Marmur, and Y. Nemerson) suggest that specific protein kinase C inhibitors, such as H7, do not block the induction of TF mRNA, more detailed analysis will be required to more fully assess the role of protein kinase C in TF induction.
The early induction of TF in arterial VSMC is particularly provocative because of the potential role these cells play in the response to vascular injury. In experimental and clinical models of percutaneous balloon angioplasty, the endothelium is denuded, exposing the medial VSMC to circulating blood and thus to a variety of agents, such as PDGF, fibroblast growth factor, angiotensin II, and a-thrombin, all apparently capable of inducing TF expression. In addition, the VSMC are exposed to coagulation factors which upon interaction with TF can initiate the clotting cascade. Thrombus formation is an early event following vessel injury (41, 42) and may result in a rapid and total occlusion of the vessel lumen. This can largely be prevented by the use of platelet inhibitors and anticoagulants (43) . Such treatment, while effective in preventing occlusive thrombosis, does not abolish the development of nonocclusive mural thrombus (44) . This nonocclusive mural thrombus may play a critical role in the development ofintimal hyperplasia by providing a foundation upon which platelets may aggregate and release growth factors. In addition, thrombin is a mitogen for cultured VSMC (45) and may play a role in stimulating proliferation in vivo.
The induction ofTF in VSMC may be critical to the formation and/or propagation of the platelet-thrombus in the early phases ofinjury. The induction ofTF by a-thrombin is particularly intriguing in that it demonstrates that a protein which is produced during activation of the coagulation cascade is capable of rapidly and markedly inducing mRNA encoding an initiator of this cascade. This raises the possibility that a positive feedback system exists whereby a-thrombin can help propagate the clot by inducing TF production in the VSMC located near the site ofthe thrombus. The findings in VSMC culture should serve as a stimulus to examine the expression of TF in VSMC in intact blood vessels under a variety ofpathologic and physiologic conditions.
